Laura N. Kuhl, BA; Bruce Ettinger, MD; Clifford J. Rosen, MD; Nananda F. Col, MD, MPP, MPH
Potential Financial Conflicts of Interest:Honoraria and consultancies: B. Ettinger (Berlex, Duramed-Barr, Eli Lilly, GlaxoSmithKline, Novartis, Proctor & Gamble, Roche, Schering-Plough), C.J. Rosen (Takeda Pharmaceuticals).
Kuhl LN, Ettinger B, Rosen CJ, Col NF. Questioning the Accuracy of a Recent Review of Osteoporosis Medications. Ann Intern Med. 2009;150:423-424. doi: 10.7326/0003-4819-150-6-200903170-00015
Download citation file:
Published: Ann Intern Med. 2009;150(6):423-424.
TO THE EDITOR:
Because the choice of osteoporosis drugs often depends on their nonskeletal effects, it is important that clinicians have access to accurate information about their benefits and risks. In this regard, the article by MacLean and colleagues (1) fails in several respects.
MacLean and colleagues report that ibandronate protects against upper gastrointestinal perforations, ulcers, and bleeding (odds ratio, 0.33 [95% CI, 0.14 to 0.74]). This finding is based on 2 studies (2, 3), neither of which reports a difference between ibandronate and placebo.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only